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E-mail address: annelaure.damont@cea.fr (A. Dam6-Fluoro-PBR28 (N-(6-fluoro-4-phenoxypyridin-3-yl)-N-(2-methoxybenzyl)acetamide), a fluorinated
analogue of the recently developed TSPO 18 kDa ligand PBR28, was synthesized and labelled with fluo-
rine-18. 6-Fluoro-PBR28 and its 6-chloro/6-bromo counterparts were synthesized in six chemical steps
and obtained in 16%, 10% and 19% overall yields, respectively. Labelling with fluorine-18 was performed
in one single step (chlorine/bromine-for-fluorine heteroaromatic substitution) using a Zymate-XP robotic
system affording HPLC-purified, ready-to-inject, 6-[18F]fluoro-PBR28 (>95% radiochemically pure). Non-
decay-corrected overall yields were 9–10% and specific radioactivities ranged from 74 to 148 GBq/lmol.
In vitro binding experiments, dynamic lPET studies performed in a rat model of acute neuroinflamma-
tion (unilaterally, AMPA-induced, striatum-lesioned rats) and ex vivo autoradiography on the same
model demonstrated the potential of 6-[18F]fluoro-PBR28 to image the TSPO 18 kDa using PET.
 2011 Elsevier Ltd. All rights reserved.Microglia activation is considered as the predominant cellular
response to inflammation within the central nervous system
(CNS). This process is characterized by a drastic change in the mor-
phology of these cells and by the notable overexpression of the
translocator protein (TSPO 18 kDa). The TSPO has been the focus
of numerous studies over several decades and is clearly recognised
as an early marker of neuroinflammation.1 This has resulted in
extensive efforts into the design of radiolabelled ligands for imag-
ing of the TSPO using PET.2–5
The 3-isoquinolinecarboxamide PK11195 was the first TSPO
ligand labelled with the short-lived positron-emitter carbon-11
(T1/2: 20.38 min).6 Today, [11C]PK11195 remains themost cited radi-
otracer in this field and is still widely used in spite of severe limita-
tions. Several newstructures belonging to other chemical classes are
now being developed as promising alternatives.7 Amongst these,
N-benzyl-N-(2-phenoxyaryl)acetamides have proved to be particu-
larly interesting candidates. Indeed, in the late 1990s, twopromisingll rights reserved.
ont).ligands DAA1097 (A) and DAA1106 (B) were identified for their
pharmacological properties relative to TSPO (Fig. 1).8–10 DAA1106
was therefore labelled with carbon-1111,12 ([11C]DAA1106, [11C]B)
and was shown to be more sensitive than the reference compound
[11C]PK11195. The discovery of [11C]DAA1106was rapidly followed
by the development of [18F]FMDAA1106 ([18F]C) and [18F]FE-
DAA1106 ([18F]D),13 two radiofluorinated counterparts, that were
evaluated14 for their potential in imaging the TSPO. Successively,
in 2005 and 2007, a novel 18F-labelled analogue of DAA1106 and
the fluorine-18 version of DAA1106, obtained both in a single radio-
synthetic step, were reported in the literature as potential TSPO
radioligands: [18F]PBR06 ([18F]E)15 and [18F]DAA1106 ([18F]B),16
respectively. [18F]PBR06 was labelled with introduction of the fluo-
rine-18 at the N-acyl function by reacting [18F]F with the corre-
sponding bromo precursor, while the synthesis of [18F]DAA1106
was achieved by the nucleophilic reaction of [18F]F with a diaryli-
odonium salt precursor. [18F]PBR06 was very recently evaluated in
monkey and rat.17,18 In 2006, [11C]DAA1097 ([11C]A) and its
[11C]methyl and [11C]ethyl homologues, [11C]F and [11C]G, respec-
tively (Fig. 1), were synthesized and evaluated as PET ligands for
Figure 1. Structures of TSPO receptor radioligands featuring an aryloxyanilide backbone and structure of 6-[18F]fluoro-PBR28 ([18F]15).
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compound [11C]PBR28 ([11C]H, Fig. 1), a closely related analogue of
[11C]DAA1106, has also been identified as a ligand displaying excep-
tional properties for the in vivo imaging of the TSPO using PET.20–26
The preparation of an 18F-analogue has also been achieved based
on an O-[18F]fluoroalkylation strategy of O-desmethyl PBR28, lead-
ing to compound [18F]FEPPA ([18F]I, Fig. 1) whose biodistribution
properties and metabolism have been studied and compared with
the parent molecule in rats.27 The bioisosteric replacement of the
C–Fmoiety present in the anilide ring of DAA1106with a ring nitro-
gen in PBR28 leaves the latter structurewith an interesting pyridine
motif leaving open the option of fluorine introduction at an a-posi-
tion.Moreover, the use of a suitable leaving group at the pyridinea-
position would offer an opportunity for fluorine-18-labelling using
thewell-established nucleophilic ortho-heteroaromatic radiofluori-
nationmethodology.28 Thiswould permit the preparation of a novel
radiofluorinated analogue, 6-[18F]fluoro-PBR28 ([18F]15), closely re-
lated to PBR28 (H) but also to compound F, circumventing themore
common above mentioned (e.g., [18F]FEDAA1106 and [18F]FEPPA)
‘fluoroalkyl derivatization strategy’. This Letter presents the synthe-
sis of 6-fluoro-PBR28 (15), its radiolabellingwith fluorine-18 and its
preliminary in vitro and in vivo evaluation as a radiotracer to image
the TSPO 18 kDa with PET.
The synthesis of non-radioactive 6-fluoro-PBR28 (15), needed
as reference compound in radiochemistry and the two radiolabel-
ling precursors (13, 14) as well as radiosynthesis of fluorine-18-la-
belled compound 6-[18F]fluoro-PBR28 ([18F]15) are depicted in
Scheme 1.
The preparation of 2-halo-5-nitro-4-phenoxypyridines 4, 5 and
6, as key intermediates, was required. These tri-substituted pyri-Scheme 1. Chemical synthesis of radiolabelling precursors (13, 14), reference compound
and conditions: (a) NaH, PhOH, THF, rt; (b) t-BuOOH, t-BuOK, DMF, 50 C; (c) POX3, tol
AcOH, NaBH3CN, MeOH, rt; (g) Ac2O, AcOH, 70 C; (h) K[18F]F-K222, K2CO3, DMSO, 165 dines were produced by carrying out the displacement of the 4-
chlorine of commercially available 4-chloro-3-nitropyridine (1)
with the phenolate anion, prior to an a-hydroxy-functionalization
at the 6-position of the pyridine ring. Thus, treatment of 4-chloro-
3-nitropyridine (1) with phenol and NaH in THF at room tempera-
ture gave 3-nitro-4-phenoxypyridine 2, which was selectively
hydroxylated at the C-6 position with tert-butyl hydroperoxide
(t-BuOOH) via vicarious nucleophilic substitution of hydrogen29,30
in presence of potassium tert-butoxide (t-BuOK) as a base in DMF.
Despite the low nucleophilicity of t-BuOK and the low reaction
temperature (50 to 30 C), compound 3 was obtained in only
moderate yield (38–45%) due to the formation of undesired 5-ni-
tro-4-tert-butoxypyridin-2-ol (10–15%). The latter side-product
formation resulted from the displacement of the very labile C-4
phenoxy group due to activation by both the ring nitrogen atom
and the ortho nitro group. Hydroxypyridine 3, isolated probably
in its pyridone form, was converted to the corresponding 2-
chloro-5-nitro-4-phenoxypyridine 4 with phosphorus oxychloride
(POCl3) in refluxing toluene. The bromo-derivative 5 was prepared
following the same strategy using POBr3 as brominating agent. The
preparation of the 2-fluoro counterpart (6) was achieved from
hydroxypyridine 3 too. The 2-hydroxy group of 3, activated by
the conjugated effects of the 5-nitro substituent and the ring nitro-
gen, was successfully replaced with fluorine when reacted with
DAST in acetonitrile at 75 C. Such a direct hydroxyl for fluorine ex-
change on an activated heteroaromatic ring using DAST, or a sim-
ilar deoxo-fluorinating agent is, to our knowledge, reported for the
first time.
Finally, 6-chloro-, 6-bromo- and 6-fluoro-PBR28 (13, 14 and 15,
respectively) were prepared according to the straightforward6-fluoro-PBR28 (15) and radiosynthesis of 6-[18F]fluoro-PBR28 ([18F]15). Reagents
uene, 110 C; (d) DAST, CH3CN, 75 C; (e) Fe, AcOH, rt; (f) 2-methoxybenzaldehyde,
C, 5 min.
Table 1
Ki values of 15 and PK11195 against [3H]PK11195 for binding affinities to TSPO
18 kDa
Compound Ki (nM, rat a) Ki (nM, rat b) Ki (nM, human c)
15 0.44 ± 0.01 3.90 ± 0.30 1.19 ± 0.03
PK11195 1.80 ± 0.04 9.30 ± 0.50 7.11 ± 0.35
a Membrane homogenates from rat heart.
b Mitochondrial fractions of rat kidney.
c Mitochondrial fractions of HEK293 cells. Values represent the mean ± SEM of at
least three independent experiments carried out in duplicate.
Table 2
Effect of TSPO ligands on pregnenolone accumulation in rat C6 glioma cells
Compound Pregnenolone release (% above control)a
15 16.45 ± 1.77
PK11195 37 ± 1
a Experimental data represents the mean ± SEM of at least three independent
experiments.
Figure 2. MicroPET axial, coronal and sagittal images (from left to right) with 6-
[18F]fluoro-PBR28 ([18F]15) in AMPA lesioned rats 60 min post-injection. Red
arrows indicate the visible right-side lesion.
Figure 3. MicroPET time-activity curves for 6-[18F]fluoro-PBR28 ([18F]15) and
[11C]PK11195 in lesioned and non-lesioned striatum of rats.
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ing 5-nitro-4-phenoxypyridine substituted in the 2-position with
either a chlorine, bromine or fluorine atom.
Reduction of nitropyridines 4, 5 and 6 was achieved with iron
dust in acetic acid yielding compounds 7, 8 and 9, respectively,
in good to excellent yields (71–98%). Reductive alkylation of
substituted 5-aminopyridines 7, 8 and 9with 2-methoxybenzalde-
hyde utilising sodium cyanoborohydride and a catalytic amount of
acetic acid in methanol, followed by acylation of the resulting com-
pounds 10, 11 and 12 using acetic acid anhydride in hot acetic acid
(70 C), gave the expected halo-analogues of PBR28, 13, 14 and 15,
respectively in good overall yields over three steps, ranging from
54% to 72%. Compounds 13–15 have been characterized using
spectroscopic techniques.32
Radioligand [18F]15was readily prepared, as shown in Scheme 1,
in a single-step procedure by nucleophilic aromatic substitution on
2-halo pyridine derivatives (13 or 14) with [18F]F using standard
conditions.33,34 The reaction was performed on a Zymate-XP ro-
botic system using activated K[18F]F–Kryptofix K222 complex as
the fluorinating reactant, in DMSO by heating at 165 C for 5 min.
After pre-purification on a C-8 PrepSep™ cartridge, [18F]15 was
purified by semi-preparative HPLC on a Waters Symmetry C-18
column and obtained in 16–18% (n >10) radiochemical decay-cor-
rected yield, based on [18F]F, starting from the bromo derivative
(14). The preparation of ready-to-inject 6-[18F]fluoro-PBR28
([18F]15) was achieved within 90 min from the end of cyclotron
fluorine-18 production, including HPLC-purification (Rt: 23–
24 min)35 and SepPak Plus-based formulation. The identity of
the product was confirmed by co-injection with an original sample
of 15 on an analytical HPLC (Rt: 1.81 min).36 As also demonstrated
by HPLC analysis, the preparation was >95% chemically and >99%
radiochemically pure. It was shown to be free of the non-radioac-
tive precursor for labelling (13, Rt: 2.25 min or 14, Rt: 2.50 min) and
was chemically and radiochemically stable for at least 120 min.
Typically, starting from a 37 GBq [18F]F batch, 3.3–3.7 GBq of 6-
[18F]fluoro-PBR28 ([18F]15) could be obtained starting from 14.
Specific radioactivities ranged from 74 to 148 GBq/lmol. Compara-
ble radiochemical yields were obtained using the chloro precursor
for labelling with however a lower observed chemical purity
(<70%). This is mainly due to the more difficult HPLC separation
of [18F]15 from its labelling precursor when using the chloro deriv-
ative 13 compared to the bromo derivative 14 (Rt: [18F]15:
23.5 min, 13: 26 min, 14: 33 min) in the conditions used.35
The measured log D7.4 (n-octanol/buffer pH 7.4 partition coeffi-
cient) and log P (n-octanol/water partition coefficient) values of
[18F]15, determined using the shake-flask method,37 were
2.82 ± 0.14 and 2.77 ± 0.10, respectively. These values are in the
range for adequate passive brain entry in vivo.38,39
The in vitro binding affinity (Ki) of 15 for TSPO was determined
by competition with [3H]PK11195 using membrane homogenates
from rat heart as well as mitochondrial-enriched preparations de-
rived from rat kidney and human embryonic kidney (HEK293)
cells.40 Compound 15 showed high affinity for TSPO as shown in
Table 1.
No significant binding of 15 to the central benzodiazepine
receptor (CBR) could be determined in competition experiments
against [3H]flunitrazepam (a reference CBR ligand) in a rat cerebral
cortex homogenate screen (concentration–response curve showed
less than 10% effect at 0.1 lM).
Compound 15 was assessed for its ability to increase pregneno-
lone synthesis by use of a well-developed steroidogenic assay.41
Practically, pregnenolone release from rat C6 cells, exposed to 6-
fluoro-PBR28 (15, 40 lM) or PK11195 (40 lM), was measured by
competitive enzyme-linked immunoassay (ELISA). Compound 15
stimulated pregnenolone synthesis at levels 17% above the base-
line, displaying lower potency than PK11195 (Table 2).MicroPET studies of 6-[18F]fluoro-PBR28 ([18F]15) using AMPA
lesioned rats42–44 resulted in images with a high contrast between
the lesioned area, indicated by the red arrows (Fig. 2), and the cor-
responding area in the intact contralateral hemisphere (ratio ipsi/
contra: 2.2) at 60 min post-injection.
The brain kinetics of [18F]15 and [11C]PK11195 in lesioned and
non-lesioned striatum are shown in Figure 3. The two radioligands
entered the brain rapidly and the maximum radioactivity uptake
was reached within 1–2 min post-injection in both regions. The
uptake of [18F]15 in the lesioned striatum remained at a plateau
to the end of the imaging experiment while the control radioli-
Figure 4. Ex vivo autoradiograms in AMPA lesioned rat brains of: (a) [18F]15 (6-
[18F]fluoro-PBR28, control), (b) [18F]15 + 15, (c) [18F]15 + PK11195 and (d)
[18F]15 + flumazenil.
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region.
Ex vivo binding experiments were also performed with [18F]15
as depicted in Figure 4: autoradiography on brain sections resulted
in a high ipsi- to controlateral ratio, which was abolished by an ex-
cess (20 nM) of non-radioactive 15 or PK11195 but not flumazenil.
In conclusion, 6-fluoro-PBR28 (15), a fluorinated analogue of
the TSPO ligand PBR28, was synthesized and labelled with fluo-
rine-18. The discussed biological evaluation studies demonstrate
the potential of this radiofluorinated tracer to image in vivo the
TSPO using PET.
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